{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:48:56Z","timestamp":1785250136278,"version":"3.55.0"},"reference-count":14,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,1,31]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>We report a case of severe hypercalcaemia after a single cycle of a combination therapy of ipilimumab and nivolumab. Initial evaluation ruled out common causes, including bone metastases, parathyroid hormone\/parathyroid hormone-related protein elevation and paraproteinaemia. Her serum 1,25-dihydroxyvitamin D (calcitriol) levels were significantly elevated following the first immunotherapy cycle. Hypercalcaemia responded only to glucocorticoid therapy, with normalisation of serum calcium and calcitriol levels. Recurrence of hypercalcaemia after glucocorticoid discontinuation and subsequent resolution with glucocorticoid re-initiation strongly supported a calcitriol-mediated mechanism, most likely as an immune-related effect of ipilimumab and nivolumab.<\/jats:p>","DOI":"10.1136\/bcr-2025-266771","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T15:23:59Z","timestamp":1770737039000},"page":"e266771","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Hypercalcaemia as an immune-related adverse event secondary to ipilimumab and nivolumab therapy in a patient with metastatic renal cell carcinoma"],"prefix":"10.1136","volume":"19","author":[{"given":"Hala","family":"Osman","sequence":"first","affiliation":[{"name":"Internal Medicine, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8899-633X","authenticated-orcid":false,"given":"Aditya","family":"Sanjeevi","sequence":"additional","affiliation":[{"name":"Internal Medicine, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-yu","family":"Hsu","sequence":"additional","affiliation":[{"name":"Nephrology, Rochester General Health System, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026021023551134000_19.2.e266771.1","article-title":"Hypercalcemia Secondary to Calcitriol Production From Dual Combination Immunotherapy in Pulmonary Metastatic Melanoma","volume":"16","author":"Strike","year":"2024","journal-title":"Cureus"},{"key":"2026021023551134000_19.2.e266771.2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-Associated Hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021023551134000_19.2.e266771.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21489"},{"key":"2026021023551134000_19.2.e266771.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-021-00825-4","article-title":"Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report","volume":"21","author":"Johnson","year":"2021","journal-title":"BMC Urol"},{"key":"2026021023551134000_19.2.e266771.5","doi-asserted-by":"publisher","DOI":"10.4103\/1947-2714.170600"},{"key":"2026021023551134000_19.2.e266771.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-021-00693-x","article-title":"Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature","volume":"21","author":"Newman","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"2026021023551134000_19.2.e266771.7","article-title":"Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia","volume":"2023","author":"Oommen","year":"2023","journal-title":"Case Rep Nephrol"},{"key":"2026021023551134000_19.2.e266771.8","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor\u2013associated hypercalcaemia","volume":"37","author":"Izzedine","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026021023551134000_19.2.e266771.9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14740\/jocmr3257w","article-title":"Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma","volume":"10","author":"Takebayashi","year":"2018","journal-title":"J Clin Med Res"},{"key":"2026021023551134000_19.2.e266771.10","doi-asserted-by":"crossref","first-page":"A169","DOI":"10.1210\/jendso\/bvab048.342","article-title":"1-25OH2D Mediated Hypercalcemia Secondary to DISR From Immune Checkpoint Inhibitors","volume":"5","author":"Disanti","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"2026021023551134000_19.2.e266771.11","doi-asserted-by":"crossref","first-page":"A232","DOI":"10.1210\/jendso\/bvac150.477","article-title":"RF30 | PSAT177 A Case of Hypercalcemia Related to Immune Checkpoint Inhibitor-Induced Sarcoidosis-like Granuloma","volume":"6","author":"Donangelo","year":"2022","journal-title":"J Endocr Soc"},{"key":"2026021023551134000_19.2.e266771.12","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0189-1"},{"key":"2026021023551134000_19.2.e266771.13","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/j.seminoncol.2015.09.006","article-title":"Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic Correlates","volume":"42","author":"Mills","year":"2015","journal-title":"Semin Oncol"},{"key":"2026021023551134000_19.2.e266771.14","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0499"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-266771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:55:50Z","timestamp":1770796550000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-266771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bcr-2025-266771"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-266771","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}